These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32758042)

  • 1. Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches.
    Colombo D; Pnevmatikou P; Melloni E; Keywood C
    Expert Rev Neurother; 2020 Oct; 20(10):1047-1064. PubMed ID: 32758042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to counter protein aggregation pathology in Parkinson's disease.
    Stott SRW; Wyse RK; Brundin P
    Prog Brain Res; 2020; 252():451-492. PubMed ID: 32247372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seven Solutions for Neuroprotection in Parkinson's Disease.
    Devos D; Hirsch E; Wyse R
    Mov Disord; 2021 Feb; 36(2):306-316. PubMed ID: 33184908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical approaches to the development of a neuroprotective therapy for PD.
    Olanow CW; Kieburtz K; Katz R
    Exp Neurol; 2017 Dec; 298(Pt B):246-251. PubMed ID: 28622912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Neurotrophic Factors in Parkinson's Disease.
    Tome D; Fonseca CP; Campos FL; Baltazar G
    Curr Pharm Des; 2017; 23(5):809-838. PubMed ID: 27928963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2020 Feb; 127(2):131-147. PubMed ID: 31993732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems.
    Rodríguez-Nogales C; Garbayo E; Carmona-Abellán MM; Luquin MR; Blanco-Prieto MJ
    Maturitas; 2016 Feb; 84():25-31. PubMed ID: 26653838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micro- and nanotechnology approaches to improve Parkinson's disease therapy.
    Torres-Ortega PV; Saludas L; Hanafy AS; Garbayo E; Blanco-Prieto MJ
    J Control Release; 2019 Feb; 295():201-213. PubMed ID: 30579984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
    Merchant KM; Cedarbaum JM; Brundin P; Dave KD; Eberling J; Espay AJ; Hutten SJ; Javidnia M; Luthman J; Maetzler W; Menalled L; Reimer AN; Stoessl AJ; Weiner DM;
    J Parkinsons Dis; 2019; 9(1):31-61. PubMed ID: 30400107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New agents promote neuroprotection in Parkinson's disease models.
    Santos CM
    CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):410-8. PubMed ID: 22483311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Drug Repurposing for Parkinson's Disease.
    Chen X; Gumina G; Virga KG
    Curr Med Chem; 2019; 26(28):5340-5362. PubMed ID: 30027839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disease-Modifying Therapy for Parkinson's Disease].
    Shimura H; Hattori N
    Brain Nerve; 2017 Feb; 69(2):159-165. PubMed ID: 28202824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.
    Tang T; Li Y; Jiao Q; Du X; Jiang H
    Neurosci Bull; 2017 Oct; 33(5):568-575. PubMed ID: 28337696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future of cell and gene therapies for Parkinson's disease.
    Isacson O; Kordower JH
    Ann Neurol; 2008 Dec; 64 Suppl 2(0 2):S122-38. PubMed ID: 19127583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.
    Paudel YN; Angelopoulou E; Piperi C; Shaikh MF; Othman I
    Pharmacol Res; 2020 Feb; 152():104593. PubMed ID: 31843673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
    Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in diagnosis and treatment of Parkinson's disease--from basic science to clinical applications.
    Storch A; Hofer A; Krüger R; Schulz JB; Winkler J; Gerlach M
    J Neurol; 2004 Sep; 251 Suppl 6():VI/33-8. PubMed ID: 15675723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.